A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats.

Abstract

© RADCLIFFE CARDIOLOGY 2021 Access at: www.ECRjournal.com Objective: It has previously been reported that curcumin prevents the development of heart failure in animal models, demonstrating that the compound is a potential treatment for the disease in humans. Although curcumin is known to be safe, its therapeutic efficiency is limited due to its low bioavailability. To overcome this problem, we developed ASD-Cur, an amorphous formulation of curcumin. In this study, we investigated the effect of ASD-Cur and compared it with Theracurmin®, a colloidal submicron dispersion of curcumin.